Top Gainers And Losers Of The Week: Saregama India Surges On Strong Q4; Nava, Clean Science Slide Amid Weak Results

Indian equity markets ended the week sharply lower, with the Nifty 50 declining 2.20 per cent and the Sensex falling 2.70 per cent amid weak global cues, rising crude oil prices, and persistent geopolitical tensions. Banking stocks remained under pressure with the Nifty Bank down 2.89 per cent, while broader markets witnessed heavy selling, with the Nifty Midcap 100 slipping 2.17 per cent and the Nifty Smallcap 100 plunging 4.56 per cent, snapping its five-week winning streak. 

Sentiment was weighed down by a sharp jump in wholesale inflation to 8.30 per cent, the highest in 42 months, a surge in Brent crude above $106 per barrel, and concerns over higher-for-longer interest rates globally.

Top Gainers of the Week

Saregama India

Saregama India was the top gainer of the week, closing at Rs 415.75, up 15.36 per cent, with volume surging to 135.23 lakh shares against the 30-week average of 6.97 lakh shares. The strong price move was backed by a robust set of Q4FY26 numbers. Revenue from operations came in at Rs 287.44 crore, up 19.4 per cent YoY, while profit before Tax jumped 26.7 per cent YoY to Rs 103.41 crore and 48.7 per cent QoQ. Profit after tax stood at Rs 74.14 crore, up 23.9 per cent YoY and 44.7 per cent QoQ. 

Biocon

Biocon was the second biggest gainer of the week, closing at Rs 430.10, up 13.07 per cent, with volume at 51.87 lakh shares against the 30-week average of 17.66 lakh shares. The rally was supported by steady Q4FY26 results. Revenue from operations grew 10 per cent YoY on an adjusted basis to Rs 4,517 crore, while EBITDA rose 29 per cent YoY to Rs 1,073 crore with a margin of 23 per cent. Reported net profit stood at Rs 126 crore for the quarter. 

Zydus Lifesciences

Zydus Lifesciences closed at Rs 1,011.70, up 7.62 per cent for the week, with volume at 8.97 lakh shares against the 30-week average of 3.58 lakh shares. The stock's gain was driven by the company's announcement of the acquisition of Assertio Holdings, a US-based specialty oncology pharmaceutical company listed on Nasdaq, for a total consideration of approximately USD 166.4 million. The deal will provide Zydus with an immediate US specialty oncology commercial footprint and access to Assertio's 170 plus community oncology accounts to build a broader oncology portfolio. 

Top Losers of the Week

Gallantt Ispat

Gallantt Ispat was the top loser of the week, closing at Rs 744.90, down 14.31 per cent, with volume at 5.43 lakh shares against the 30-week average of 7.34 lakh shares. The sharp decline came despite the company reporting a reasonable set of Q4FY26 numbers. Revenue grew 12.4 per cent YoY to Rs 1,204.8 crore, while EBITDA rose 7.3 per cent YoY to Rs 208.9 crore, though EBITDA margin contracted 82 basis points YoY to 17.3 per cent. Profit after tax came in at Rs 122.8 crore, up 5.6 per cent YoY, with PAT margin declining 60 basis points YoY to 10.2 per cent. 

Clean Science and Technology 

Clean Science and Technology was the second biggest loser of the week, closing at Rs 766.65, down 14.16 per cent, with volume at 2.05 lakh shares against the 30-week average of 1.74 lakh shares. The stock's decline was weighed down by a weak set of Q4FY26 consolidated results. Total revenue fell 6 per cent YoY to Rs 249 crore, while EBITDA declined 9 per cent YoY to Rs 96 crore, though it improved 33 per cent QoQ. EBITDA margin stood at 38.9 per cent against 41 per cent in Q4FY25. Profit before tax fell 22 per cent YoY to Rs 78 crore and profit after tax came in at Rs 58 crore, down 22 per cent YoY. 

Nava

Nava Limited was the third biggest loser of the week, closing at Rs 628.50, down 13.55 per cent, with volume at 5.48 lakh shares against the 30-week average of 2.83 lakh shares. The decline was triggered by a sharp fall in profitability in Q4FY26. Revenue from operations grew 12.2 per cent YoY to Rs 1,142.8 crore, while EBITDA was largely flat at Rs 423.2 crore, up just 1 per cent YoY, with EBITDA margin contracting sharply to 35.4 per cent from 39.7 per cent in Q4FY25. Profit after tax fell 55 per cent YoY to Rs 136.3 crore, primarily driven by a surge in tax expense, with PAT margin declining to 11.4 per cent from 28.7 per cent in Q4FY25. 

Share your thoughts in the comments below.

Disclaimer: This article is for informational purposes only and not investment advice.